June 21, 2011- Amni BioScience SAL (AMNI) announced Monday (June 20) in a statement the signing of a long-term agreement with Clinique Du Levant Société Médicale SAL (LEVANT).

The agreement will initiate a wide array of therapies involving the use of adult stem cell products manufactured by Stemedica Cell Technologies under the approval of the United States Food and Drug Administration (FDA), the statement said.

The Levant Clinic was established in 2004 by Dr. Antoine Maalouf, currently CEO. Amni BioScience is part of the Amni Company group chaired by Mr. Sam Alkhass. The company specializes in representing new medical technology to medical institutions in the MENA region. It has partnered with Stemedica as their exclusive agent to represent its array of stem cell and stem cell factor products.

Stem cell treatments are a type of intervention strategy that introduces new cells into damaged tissue in order to treat disease or injury. Medical researchers anticipate that the stem cell therapy will soon be able to treat cancer, diabetes, Parkinson's disease, cardiac failure, muscle damage and neurological disorders, and many others.

The agreement between AMNI and LEVANT calls for the pro-active implementation of clinical trials using adult stem cells as manufactured by Stemedica Cell Technologies, located in California. The statement said Stemedica’s product line will be imported into Lebanon by Benta Pharmaceutical, a well-known local Pharmaceutical Manufacturing Company.

According to the statement, AMNI is working closely with the Ministry of Health, and the Order of Physicians to establish regulatory guidelines that protect patients and create standards for safety and efficacy.